Latest News
Wyss Institute at Harvard to Utilize FairJourney Biologics Expertise in Antibody Discovery Collaboration
Wyss Institute at Harvard to Utilize FairJourney Biologics Expertise in Antibody Discovery Collaboration FairJourney Biologics to co-develop antibody compounds that would shuttle drugs to the brain via known and novel targets The collaboration will see FairJourney...
Hubrecht Institute licenses Flow Eighteen38 reagent antibodies for cancer research
Hubrecht Institute licenses Flow Eighteen38 reagent antibodies for cancer research Antibodies generated by Flow Eighteen38 to be used as research tools by Hubrecht Institute. Agreement to leverage FairJourney Biologics llama naïve libraries. Porto, Portugal and...
FairJourney Biologics enters next-generation antibody discovery collaboration with argenx
FairJourney Biologics enters next-generation antibody discovery collaboration with argenx Collaboration to leverage IONTAS proprietary mammalian display technology Differentiated antibody candidates that emerge from collaboration may advance into argenx immunology...
FairJourney Biologics enters next-generation antibody discovery collaboration with argenx
FairJourney Biologics enters next-generation antibody discovery collaboration with argenx Collaboration to leverage IONTAS proprietary mammalian display technology Differentiated antibody candidates that emerge from collaboration may advance into argenx immunology...
IONTAS and FairJourney Biologics enter antibody discovery agreement with Quell Therapeutics
Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline Cambridge, UK, Porto, Portugal, and London, UK – 08 March 2021: IONTAS Limited (IONTAS) and FairJourney...
FairJourney Biologics Group introduces Flow Eighteen38 for protein production and antibody characterization services
Porto, Portugal, 8th February 2021: FairJourney Biologics (FJB) and IONTAS, leaders in the discovery and optimization of antibodies, have today announced the launch of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterization data on antibody panels and leads.
